Table 3.
Predictors distribution according to the American Society of Gastrointestinal Endoscopy (ASGE) and the European Society of Gastrointestinal Endoscopy (ESGE) risk group criteria
| Risk groups with their associated criteria | ASGE 2019 | ESGE | ||
|---|---|---|---|---|
| CBD stone status, n (%) | CBD stone status, n (%) | |||
| Positive | Negative | Positive | Negative | |
| Low risk | 1 (8.3) | 11 (91.7) | 8 (26.7) | 22 (73.3) |
| Intermediate risk | 50 (34.3) | 96 (65.7) | 58 (38.9) | 91 (61.1) |
| Abnormal LFTs | 29 (33.7) | 57 (66.3) | 44 (41.1) | 63 (58.9) |
| Age > 55 years | 34 (35.8) | 61 (64.2) | NA | |
| Dilated CBD on imaging | 33 (37.1) | 56 (62.9) | 48 (43.6) | 62 (56.4) |
| High risk | 267 (73.6) | 96 (26.4) | 252 (73.7) | 90 (26.3) |
| Cholangitis | 155 (73.8) | 55 (26.2) | 155 (73.8) | 55 (26.2) |
| CBD stone on imaging | 197 (77.3) | 58 (22.7) | 197 (77.3) | 58 (22.7) |
| TB > 4 mg/dL and dilated CBD on imaging | 64 (86.5) | 10 (13.5) | NA | |
CBD, common bile duct; LFT, liver function test; NA, not available; TB, total bilirubin.